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Moxifloxacin cerebrospinal fluid (CSF) penetration was eval-
uated by obtaining full plasma and CSF time concentration
curves for 4 patients with tuberculous meningitis. The geo-
metric mean ratio of the areas under the curve for CSF to
plasma were 0.82 (range, 0.70–0.94) at 400 mg once per day
and 0.71 (0.58–0.84) at 800 mg once per day.
The outcome of tuberculous meningitis (TBM) is dominated by
diagnostic delay and limited therapeutic options, because of ad-
verse effects or resistance to first-line drugs, as well as poor
cerebrospinal fluid (CSF) penetration of some of the first- and
second-line drugs. The combination of isoniazid, rifampicin,
pyrazinamide, and ethambutol or streptomycin is recommended
for the treatment of TBM by the World Health Organization.
However, this schedule is not based on strong scientific evidence;
no randomized, controlled trials or extensive pharmacokinetic
studies have supported these recommendations.
Moxifloxacin, which has the highest in vitro activity against
Mycobacterium tuberculosis, compared with the other quino-
lones [1], has emerged as the most promising second-line agent
for treatment of tuberculosis if adverse effects or drug resistance
limit the use of first-line agents. Although moxifloxacin is not
approved for tuberculosis treatment, it appeared to be well
tolerated at a dose of 400 mg during long-term treatment of
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pulmonary tuberculosis [2]. This drug has shown the potential
to shorten tuberculosis treatment in the murine model and is
being evaluated in clinical trials as a first-line agent that may
enable shortening of treatment. On the basis of in vitro and
in vivo studies, it has been suggested that a moxifloxacin dosage
of 800 mg once per day can suppress resistance [3], but no
safety data are available to support administration of this dos-
age. Moxifloxacin cannot be recommended yet for standard use
in the treatment of TBM, because there is a paucity of data on
the CSF penetration of moxifloxacin in humans [4, 5], and
animal data have revealed variability in the CSF penetration of
moxifloxacin [6, 7]. In addition, plasma drug concentrations
of moxifloxacin are lowered by 30% by coadministration of
rifampicin [8]. Therefore, additional studies involving humans
are needed to measure plasma and CSF concentrations of mox-
ifloxacin over time to establish the optimal dose for treatment
of TBM.
Material and methods. Moxifloxacin was administered at
an oral dosage of 400 mg once per day for at least 5 days,
followed by 800 mg once per day. Plasma and CSF concentra-
tions were evaluated twice (after each fifth dose; steady-state)
[9]. The local ethics committee of the University Medical Cen-
tre Groningen approved the treatment protocol and informed
consent of all included patients was obtained.
Blood and CSF samples were collected before moxifloxacin
administration and at 1, 2, 4, 8, 12, and 24 h after adminis-
tration of the dose. For plasma and CSF sampling, a peripheral
intravenous catheter and an external lumbar drain were in-
serted. Patency of the peripheral catheter was maintained by a
saline drip. Before a blood sample was taken, the drip was
stopped, and the first 4 mL of blood were discarded. Total
(protein-bound plus -unbound) concentrations were assessed
in plasma and CSF samples using a validated method on high-
performance liquid chromatography with fluorescence detec-
tion [8] and unbound concentrations (which represent the drug
that can cross biological barriers and interact with the bacte-
rium) were assessed following ultrafiltration (Centrifree Ultra-
filtration device; Millipore). Pharmacokinetic parameters were
assessed with standard noncompartmental pharmacokinetic
methods using the software package MWPharm, version 3.60
(Mediware). Ratios of the area under the concentration-time
curves up to 24 h after administration of the dose (AUC0–24h)
in CSF versus plasma were calculated to express the penetration
of moxifloxacin in CSF. The patients’ M. tuberculosis isolates
were subjected to drug susceptibility testing with use of the
Middlebrook 7H10 agar dilution method [10]. The ratio of the
 at K
atholieke U






BRIEF REPORT • CID 2009:49 (1 October) • 1081







400 mg 800 mg 400 mg 800 mg
AUC0–24h, mg h/L 24.4 (20.5–24.5) 38.3 (32.2–42.4) 18.1 (14.8–19.8) 28.4 (24.9–28.9)
Cmax, mg/L 2.57 (1.79–3.47) 3.65 (3.31–4.09) 1.29 (1.04–1.50) 2.22 (1.72–2.63)
Tmax, h 1.0 (1.0–1.3) 2.0 (2.0–2.5) 4.0 (3.8–5.5) 4.0 (3.8–5.5)
Cmin, mg/L 0.21 (0.17–0.26) 0.37 (0.24–0.48) 0.19 (0.14–0.24) 0.33 (0.25–0.38)
T1/2, h 6.7 (6.0–7.5) 5.8 (5.0–10.0) 6.0 (5.7–7.3) 7.0 (6.4–7.4)
Cl/F, L/h 14.9 (12.6–30.6) 19.2 (15.3–24.62) 18.8 (17.5–34.6) 25.7 (24.2–31.2)
Vd, L 159 (143 161) 140 (139–142) NA NA
Geometric mean AUC/MIC ratio (range) 103 (60–196) 186 (132–322) 84 (56–154) 132 (95–226)
Unbound AUC/MIC ratio
Patient 1 39 118 NA NA
Patient 2 98 193 NA NA
NOTE. Data are median values (interquartile range), unless otherwise indicated. AUC0–24h, area under the concentration-time curve
from 0 to 24 h; CL, total clearance; Cmin, trough concentration of drug; Cmax, maximum concentration of drug; NA, not applicable; Tmax,
time to maximum concentration of drug in serum; t1/2, terminal elimination half-life; Vd, volume of distribution.
AUC0–24h and the minimal inhibitory concentration (MIC) was
calculated, because the AUC0–24h/MIC ratio has been proposed
to be the best pharmacokinetic/pharmacodynamic parameter
to predict in vivo efficacy of fluoroquinolones against fast-
growing gram-negative bacteria [11] and M. tuberculosis [12].
To assess the AUC0–24h/MIC more accurately, these values were
also calculated for unbound drug concentrations [11]. To assess
the safety of moxifloxacin at a higher dosage, the serum glucose
level was determined, and liver and renal function tests were
performed. Electrocardiography monitoring was performed to
assess possible QTc prolongation.
All results are presented as median values with interquartile
ranges (IQRs). Because data were not normally distributed,
nonparametric tests (ie, the Wilcoxon signed-rank test and the
Spearman correlation test) were used in the statistical analysis.
Results. Four male patients were referred to our center for
treatment of TBM during the period 2007–2008; the diagnosis
was confirmed by leptomeningeal biopsy or CSF analysis; M.
tuberculosis culture results were positive for all of the patients.
Their median age was 47 years (IQR, 30–65 years), and the
median body mass index (calculated as weight in kilograms
divided by the square of height in meters) was 21.1 (IQR, 16.7–
21.7). All patients had received rifampicin (600 mg once per
day) and moxifloxacin (400 mg once per day). One patient
received additional isoniazid.
During pharmacokinetic studies, the CSF was colorless and
clear; the median total protein value was 0.6 g/L (IQR, 0.5–0.7
g/L; normal range, 0.3–0.7 g/L), the median glucose level was
2.5 mmol/L (IQR, 2.4–2.8 mmol/L; normal range, 2.2–4.4 mmol/
L), and the median mononuclear cell count was cells/621 10
L (IQR, 15– cells/L; normal range, 0– cells/L).6 625 10 3 10
MICs of moxifloxacin for M. tuberculosis ranged from 0.125 to
0.25 mg/L. Pharmacokinetic and pharmacodynamic parameters
are shown in Table 1. The geometric mean AUCCSF/AUCPlasma
ratio for total (bound plus unbound) concentrations was 0.82
(range, 0.70–0.94) at 400 mg once per day; this was not signif-
icantly different from the geometric mean AUCCSF/AUCPlasma
ratio of 0.71 (range, 0.58–0.84) at 800 mg once per day
( ). Unbound concentrations could be measured in 2Pp .3
patients. The unbound fractions of moxifloxacin were 40%
and 60% in serum and 90% and 95% in CSF, both at doses of
400 mg and 800 mg. In these patients, the unbound AUCCSF/
AUCPlasma ratios were 1.31 and 1.75 at a dose of 400 mg and
0.85 and 1.16 at a dose of 800 mg.
After administration of 400 mg and 800 mg of moxifloxacin,
the AUCCSF was significantly related to the peak concentration
in CSF ( ; ). The time to reach the maximumRp 0.8 P ! .001
concentration in CSF was significantly longer than the interval
needed for plasma ( ).Pp .002
Two patients continued therapy with moxifloxacin at 600 mg
once daily for 2 months and 8 months, 1 patient continued
therapy at 400 mg once daily for 9 months, and 1 patient con-
tinued treatment at 800 mg once daily for 4 months. During
treatment with moxifloxacin, no adverse effects were reported
that could be attributed to moxifloxacin, based on the evalu-
ation of electrocardiograms, serum glucose levels, and blood
sampling of renal and liver function.
Discussion. We describe a combined CSF and plasma mox-
ifloxacin concentration measurement over time in 4 patients
treated for TBM during steady-state conditions. We show that
moxifloxacin penetrates readily in CSF. This confirms earlier data
on CSF penetration, which were based only on a single CSF
sample, in patients undergoing a scheduled urological operation
[5]. The data for our patients with TBM indicate complete CSF
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concentration-time curves, which is the gold standard to assess
CSF/plasma ratios. This adds important information to the cur-
rent knowledge and enables pharmacokinetic/pharmacodynam-
ic parameter calculations. On the basis of unbound AUCCSF/
AUCplasma ratios, an accumulation of moxifloxacin in CSF could
be observed. Assuming that the AUC/MIC ratio, based on total
drug concentration, is the best predictive model for efficacy for
fluoroquinolones, the value of 100 has to be exceeded [13], but
protein binding differs among the range of fluoroquinolones—
and only the unbound drug fraction is antimicrobially active. In
our 2 patients, in whom we measured unbound drug, we ob-
served a considerable difference in the unbound concentration
of moxifloxacin that could not be explained by moxifloxacin
concentration–dependent protein binding [12]. To interpret the
value of the AUC/MIC in patients to guide individual dosing
is therefore difficult. Because all patients received rifampicin,
which generally results in a nearly 30% reduction in the AUC
[8] of moxifloxacin, it might be considered to increase the
dosage of moxifloxacin to achieve moxifloxacin concentrations
similar to those without rifampicin. Because the peak moxi-
floxacin level has good predictive value for the AUC, a CSF
sample could be obtained 4 h after ingestion of the drug as a
means to predict and verify the resulting CSF exposure. Al-
though moxifloxacin-induced QTc prolongation should be as-
sessed when a dosage is increased, significant prolongation was
observed at higher AUCs of ∼86 mg  h/L, which is 2 times
higher than in our study [14]. As a next step, we propose
designing a prospective study to evaluate the efficacy and safety
of dosing of moxifloxacin in patients with tuberculosis based
on unbound AUCplasma/MIC ratios.
Adequate moxifloxacin concentrations were achieved in CSF
and in plasma using dosages of 400 mg to 800 mg once per day.
Monitoring of moxifloxacin concentration levels may be war-
ranted in patients who are concurrently taking an interacting
medication or for whom there is a high in vitro MIC. These data
suggest that moxifloxacin is an important addition in the treat-
ment of TBM.
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